David R. Gandara

TL;DR: Veliparib, paclitaxel, and carboplatin were well tolerated and demonstrated promising antitumor activity and the recommended phase 2 dose (RP2D), maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics (PK) of veliparIB combined with paclitrixel and carbplatin were determined.

TL;DR: In the emerging era of new anticancer agents directed against molecular targets present in only a small subset of patients within a general population, such as non‐small-cell lung cancer (NSCLC), it is increasingly important to consider simultaneous and early codevelopment of an associated predictive biomarker.

TL;DR: The survival result achieved was superior to prior SWOG experiences; however, the toxic death rate was unacceptably high in PS-2 patients.

TL;DR: While single-agent selumetinib has no significant activity in STS, the combination may be active for leiomyosarcomas.

TL;DR: This study found that response and progression-free survival were highly associated with EGFR mutation status, and patients with tumors harboring EGFR TK domain mutations did much better with gefitinib, whereas those with wild-type EGFR tumors fared better with chemotherapy, despite near uniformity in clinical factors that would have suggested superior outcomes with gEFITinib.